News

The first patient has been dosed in the phase 1b/2 trial of ERAS-007, an extracellular signal-regulated kinase inhibitor, for the treatment of advanced non-small cell lung cancer.

Onvansertib has demonstrated positive efficacy and safety in patients with KRAS-mutant metastatic colorectal cancer.

The first patient with a locally advanced or metastatic solid tumor has been dosed with buparlisib in combination with A0025 with or without atezolizumab in a phase 1a clinical trial.

Alicia K. Morgans, MD, PhD, discusses the cardiovascular risks associated with androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer.

Sotorasib leads to intracranial responses in patients with KRAS G12C-mutated non–small cell lung cancer, according to an update from CodeBreaK 100.

Zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor, was safe and effective in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma carrying chromosome 17p13.1 deletion.

In an interview, Amaia Lujambio, MD discussed the diversity of genomic alterations in hepatocellular and advanced in molecular testing that could shape future understanding of the disease.

In an interview with Targeted Oncology, Michael Kolodziej, MD, the senior advisor for ADVI Health as well as an American College of Physicians Fellow, discussed the impact the COVID-19 pandemic has had on oncology practice. 

The addition of ramucirumab to gemcitabine in the second-line setting led a survival advantage for patients malignant pleura mesothelioma.

Bishoy M. Faltas, MD, discussed the use of genomic testing in urothelial canncer in greater detail, in an interview with Targeted Oncology.

The phase 2 NOVA-II study has completed its part 1 analysis of OQL011 for the treatment of cancer therapy-induced skin toxicities.

Elisa Agostinetto, MD, of the Istituto Clinico Humanitas in Rozzano, Milan, Italy, discussed the rational of investigating the accuracy of PREDICT+ in HER2-positive breast cancer.

A study has shown that high interferon signaling and expression of MHC-II related genes can predict response to therapy is patients with advanced heptocellular carcinoma being treated for the first time.

Atezolizumab given in combination with bevacizumab led to an improvement in overall survival compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma.

Cancer research sites across the United States are evaluating the use of TTI-622 plus azacitidine in patients with T53-mutated acute myeloid leukemia.

Patients with inoperable intrahepatic cholangiocarcinoma have demonstrated tendency to live longer when elective internal radiation therapy with Y90 is added to chemotherapy.

Efficacy and safety have been demonstrated with the combination of durvalumab with tremelimumab and transcatheter arterial chemoembolization or radiofrequency ablation in advanced hepatocellular carcinoma.

In an interview with Targeted Oncology™, Rajneesh Nath, MD, discussed the need for novel treatment for elderly patients with relapsed/refractory AML and how the SIERRA trial is designed to help.

Retrospective data show a low prevalence of esophagitis among immune checkpoint inhibitor-related adverse event in patient with cancer.

In an interview with Targeted Oncology, Rodney P. Rocconi, MD, FACOG, discussed the analysis of the homologous recombination proficient patients with advanced-stage ovarian cancer treated in the phase 2 VITAL study as well as a biomarker analysis.

Clinicians affiliated with the National Community Oncology Dispensing Association, Inc have launched the Intravenous Cancer Treatment Education website, as educational resource for patients.

To address toxicities related to cellular therapy, MD Anderson Cancer Center will now offer the CaspaCIDe safety switch from Bellicum Pharmaceuticals.

In an interview with Targeted Oncology™, Cathy Eng, MD, FACP, FASCO, discussed existing and novel biomarkers in anal cancer and ongoing research in the space.

In an interview with Targeted Oncology™, Ming Zhao, MD, discussed how the efficacy of HAIC-FO for the treatment of HCC compares to sorafenib as investigated in the FOHAIC-1 clinical trial.

The phase 3 PANTHER study of pevonedistat plus azacitidine for the treatment of 3 hematologic malignancies has missed its primary end point.

Today, Cancer Treatment Centers of America announced a new partnership with MedAllies to help keep providers informed about the new CoP notification requirements from the Centers for Medicare & Medicaid Services.

Two international studies of oregovomab in combination with other anticancer therapies for the treatment of previously treated, recurrent ovarian cancer have dose its first patients, and patients are being recruited to receive the drug in a phase 3 study conducted in the United States.

Gavocabtagene autoleucel has been granted orphan drug designation from the FDA and is being investigated in other solid tumors in a phase 1/2 clinical trial.

A biologics license application has been submitted to the FDA seeking approval for toripalimab in combination with 2 chemotherapy agents to treat metastatic nasopharyngeal carcinoma in the front-line setting and single-agent toripalimab to treat patients in the second-line setting.

Erica Stringer-Reasor, MD discusses the results of a phase 2 study examining the combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive breast cancer with leptomeningeal metastasis.